Filter News

Roka Bioscience To Report Fourth Quarter And Full Year 2016 Financial Results

Published: Mar 03, 2017

WARREN, N.J., March 2, 2017 /PRNewswire/ -- Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, announced plans to release its financial results for the fourth quarter and full year of 2016 on March 9, 2017 after the close of the financial markets.

Roka Bioscience will also host a conference call at 4:30 p.m. Eastern Time on March 9, 2017 to discuss its fourth quarter financial results. During the conference call, material information concerning the Company, its operations, strategies and prospects may be discussed.

To listen to the conference call live, go to http://rokabio.investorroom.com/ or dial 1-888-347-1331 for domestic callers and 1-412-902-4277 for international callers.  A replay of the conference call will be available after the completion of the call by dialing 1-877-344-7529 (domestic) and 1-412-317-0088 (international). The replay access code is 10102626. An online archive of the conference call will also be available at http://rokabio.investorroom.com/.

About Roka Bioscience

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result-out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. 

Contact:

Investor Contact:
Roka Bioscience, Inc.
ir@rokabio.com
855-ROKABIO (855-765-2246)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/roka-bioscience-to-report-fourth-quarter-and-full-year-2016-financial-results-300417160.html

SOURCE Roka Bioscience, Inc.

Back to news